The analysis revealed that nearly two thirds of metastatic melanoma samples (29 of 43) collected after MAPKi-resistance development had a reduced expression of p73 mRNA relative to the level in the corresponding tumour samples collected before the therapy start from the same patient (Fig. 2f). The gene discussed is TP73; the disease is neoplasm.